Given the heterogeneity of major diagnostic symptoms, Aβ/tau pathology, memory impairments, and neurological dysfunction among AD patients, single-target drugs are unlikely to be sufficient therapies. The gene discussed is MAPT; the disease is Alzheimer disease.